Echocardiography-based qualification and response assessment to cardiac resynchronisation therapy in patients with chronic heart failure. The matrix metalloproteinase-9 substudy

Kardiologia Polska

Volumn 69, Issue 10, 2011, Pages 1043-1051

  Szulik, Mariola ^a   Stabryła Deska, Joanna ^a   Boidol, Joanna ^a   Lenarczyk, Radosław ^a   Kalarus, Zbigniew ^a   Kukulski, Tomasz ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Cardiac resynchronisation therapy; Echocardiography; Heart failure; Metalloproteinase

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; GELATINASE B;

ADULT; AGED; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MALE; OXYGEN CONSUMPTION; QRS COMPLEX; SENSITIVITY AND SPECIFICITY; TISSUE DOPPLER IMAGING;

EID: 80054728034     PISSN: 00229032     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Vardas PE, Auricchio A, Blanc JJ et al. Guidelines for cardiac pacing and resynchronization therapy. The task force for cardiac pacing and resynchronization therapy of the European Society of Cardiology. Developed in collaboration with European Heart Rhythm Association. Eur Heart J, 2007; 28: 2256-2295. (Pubitemid 47428944)
2. Hunt SA, Abraham WT, Chin MH et al. ACC/AHA 2005 Guideline Update for the Management of Patients With Chronic Heart Failure in the Adult. A Report of the American College of Cardiology/ American Heart Associaton Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol, 2005; 46: 1116-1143. (Pubitemid 41316527)
3. Remme WJ, Swedberg K. Task force for the diagnosis and treatment of chronic heart failure. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J, 2001; 22: 1527-1566.
4. Daubert JC, Ritter P, Le Breton H et al. Permanent left ventricular pacing with transvenous lead inserted into the coronary veins. Pacing Clin Electrophysiol, 1998; 21: 239-245.
5. Lenarczyk R, Kowalski O, Sredniawa B et al. Triple-site versus standard cardiac resynchronization therapy study (TRUST CRT): clinical rationale, design, and implementation. J Cardiovasc Electrophysiol, 2009; 20: 658-662.
6. Dickstein K, Cohen-Solal A, Filippatos G et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. The task force for diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC HFA and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J, 2008; 29: 2388-2442.
7. Lappegård KT, Bjørnstad H. Anti-inflammatory effect of cardiac resynchronization therapy. PACE, 2006; 29: 753-758. (Pubitemid 44060744)
8. Thomas JD, Adams DB, DeVries D et al. Guidelines and recommendations of digital echocardiography. A report from the Digital Echocardiography Committee of the American Society of Echocardiography. J Am Soc Echocardiogr, 2005; 18: 287-297. (Pubitemid 40289057)
9. Myers J, Gullestad L, Vagelos R et al. Clinical, hemodynamic and cardiopulmonary exercise test determinants of survival in patients referred for evaluation of heart failure. Ann Intern Med, 1998; 129: 286-293. (Pubitemid 28394573)
10. Auricchio A, Stellbrink, C Butter C et al. Clinical efficacy of cardiac resynchronization therapy using left ventricular pacing in heart failure patients stratified by severity of ventricular conduction delay. J Am Coll Cardiol, 2003; 42L: 2109-2116. (Pubitemid 37549894)
11. Yu CM, Fung JWH, Zhang Q et al. Improvement of serum NT-proBNP predicts improvement in cardiac functional favorable prognosis after cardiac resynchronization therapy for heart failure. J Card Fail, 2005; 11 (suppl. 5): 42-46.
12. Sundstrom J, Evans JC, Benjamin EJ et al. Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study. Circulation, 2004; 109: 2850-2856. (Pubitemid 38786446)
13. Wagner DR, Delagardelle C, Ernens I, Rouy D, Vaillant M, Beissel J. Matrix metalloproteinase-9 is a marker of heart failure after acute myocardial infarction. J Card Fail, 2006; 12: 66-72. (Pubitemid 43267754)
14. Webb CS, Bonnema DD, Ahmed SH et al. Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling. Circulation, 2006; 114: 1020-1027. (Pubitemid 44358878)
15. Tziakas DN, Chalikias GK, Papaioakeim M et al. Comparison of levels of matrix metalloproteinase-2 and -3 in patients with ischemic cardiomyopathy versus nonischemic cardiomyopathy. Am J Cardiol, 2005; 96: 1449-1451. (Pubitemid 41566631)
16. Spinale FG. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res, 2002; 90: 520-530. (Pubitemid 34640901)
17. Hessel MHM, Bleeker GB, Bax JJ et al. Reverse ventricular remodeling after cardiac resynchronization therapy is associated with a reduction in serum tenascin-C and plasma matrix metalloproteinase-9 levels. Eur J Heart Fail, 2007; 9: 1058-1063. (Pubitemid 47451814)
18. Matsunaga T, Abe N, Kameda K et al. Circulating level of gelatinase activity predicts ventricular remodeling in patients with acute myocardial infarction. Int J Cardiol, 2005; 105: 203-208. (Pubitemid 41512488)
19. Squire IB, Evans J, Ng LL, Loftus IM, Thompson MM. Plasma MMP-9 and MMP-2 following acute myocardial infarction in man: correlation with echocardiographic and neurohumoral parameters of left ventricular dysfunction. J Card Fail, 2004; 10: 328-333. (Pubitemid 39092685)
20. Breithardt OA. Conventional echocardiography. In: Yu CM, Hades DL, Auricchio A eds. Cardiac resynchronization therapy. Blackwell Futura, London 2006: 76-89.
21. Cleland JG, Daubert JC, Erdmann E et al. The effect of cardiac resynchronization therapy on morbidity and mortality in heart failure (the Cardiac Resynchronization-Heart Failure [CARE-HF] Trial). N Engl J Med, 2005; 352: 1539-1549. (Pubitemid 40517094)
22. Kass D. Pathophysiology of cardiac dyssynchrony and resynchronization. In: Ellenbogen KA, Kay GN, Wilkoff BL eds. Device therapy for congestive heart failure. 1st Ed. Saunders, Philadelphia 2004: 27-47.
23. Bleeker GB, Schalij MJ, Molhoek SG et al. Relationship between QRS duration and left ventricular dyssynchrony in patients with end-stage heart failure. J Cardiovasc Electrophysiol, 2004; 15: 544-549. (Pubitemid 38621905)
24. Bax JJ, Bleeker GB, Marwick TH et al. Left ventricular dyssynchrony predicts response and prognosis after cardiac resynchronization therapy. J Am Coll Cardiol, 2004; 44: 1834-1840. (Pubitemid 39424084)
25. Yu CM, Fung WH, Lin H, Zhang Q, Sanderson JE, Lau CP. Predictors of left ventricular reverse remodeling after cardiac resynchronization therapy for heart failure secondary to idiopathic dilated or ischemic cardiomyopathy. Am J Cardiol, 2002; 91: 684-688.
26. Yu CM, Fung JW, Zhang Q et al. Tissue Doppler imaging is superior to strain rate imaging and postsystolic shortening in the prediction of reverse remodeling in both ischemic and nonischemic heart failure after cardiac resynchronization therapy. Circulation, 2004; 110: 66-73. (Pubitemid 38880135)
27. Chung ES, Leon AR, Tavazzi L et al. Results of the Predictors of Response to CRT (PROSPECT) Trial. Circulation, 2008; 117: 2608-2616.